Navigation Links
Penn collaborates on $8 million Barrett's esophagus research network
Date:11/3/2011

PHILADELPHIA - A research group at the Perelman School of Medicine of the University of Pennsylvania, led by John Lynch, MD, PhD, assistant professor of Medicine in the Division of Gastroenterology, has received a National Cancer Institute (NCI) grant to establish a Barrett's esophagus translational research network (BETRNet) with Columbia University (led by Dr. Timothy Wang) and the Mayo Clinic (led by Dr. Kenneth Wang). The award is for nearly $8 million across all sites.

Barrett's esophagus (BE) is an increasingly prevalent, pre-cancerous disorder that results primarily from reflux of acid and bile. It afflicts millions of Americans and is a precursor to esophageal adenocarcinoma (EAC), which has the fastest rate of increase of any cancer in the US.

Co- principal investigators are Lynch, Gary Falk, MD, professor of Medicine; Greg Ginsberg, MD, professor of Medicine and director of endoscopy; Antonia Sepulveda, MD, PhD, professor of Pathology and Laboratory Medicine, and Anil K. Rustgi, MD, T. Grier Miller professor of Medicine and chief of the Division of Gastroenterology. Drs. Rustgi, Timothy Wang and Kenneth Wang direct the BETRNet's coordination with two other funded institutions -- the University of Michigan as and Case Western Reserve University -- in conjunction with the NCI and Vanderbilt University (coordinating center).

"We are all very excited to be a part of this multicenter research network," says Lynch. "Our understanding of the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma has lagged behind that of other cancers because we have not yet developed physiologically relevant laboratory models and an integrated research network, both of which are supported by this award."

The award provides for a multidisciplinary, translational research program to study the origins and pathogenesis of the disorder. The team, which has collaborated in the past, will focus on the role of chronic inflammation and bile acids in the upregulation of molecular pathways and stem/progenitor cells, and possible ways to target these cells for developing preventive and therapeutic treatments.

The Penn project members will bring to the network a large patient population and Barrett's inflammatory animal models. Three main projects comprise the network's goals:

  • Identify the role of Notch signaling proteins in animal models of Barrett's esophagus to determine the effects of Notch inhibition or Notch activation on progression to cancer.
  • Characterize the stem/progenitor cell of origin in Barrett's esophagus in mouse models. A pilot clinical trial using an antagonist of a G-protein coupled receptor expressed on stem/progenitor cells upregulated in the disease will be conducted to determine if regression of Barrett's esophagus occurs.
  • Identify novel biomarkers and gene signatures in Barrett's esophagus, correlating data sets from animal and human models to clarify which cells play the most important role in disease progression. A cohort of patients undergoing radiofrequency ablation for Barrett's esophagus will be assembled to identify biomarkers of response to therapy and to study the development of BE.

"Our novel preclinical models serve as the foundation for testing hypotheses, which are then brought ultimately to the clinic in a true translational 'bench-to-bedside' approach through biomarker, chemoprevention and therapeutic studies," says Rustgi.

The other subtype of esophageal cancer is esophageal squamous cell carcinoma (ESCC), which is common worldwide. Penn investigators have a long-standing NCI-funded program project in this cancer, dating to 2003, funded to nearly $10 million every five years. This group's Principal Investigator is also Dr. Rustgi; other investigators include Penn researchers Dr. J. Alan Diehl, professor of Cancer Biology and director of cancer cell biology in the Abramson Family Cancer Research Institute; Dr. Hiroshi Nakagawa, research associate professor of Medicine; Dr. Phyllis Gimotty, professor of Biostatistics; Dr. Jonathan Katz, assistant professor of Medicine; Dr. Gary Wu, professor of medicine; and Dr. Sunil Singal, assistant professor of Surgery, as well as Dr. Meenhard Herlyn, professor at the Wistar Institute and Dr. Andres Klein-Szanto at Fox Chase Cancer Center, collaborating with groups at Massachusetts General Hospital and Dana Farber Cancer Institute.


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Philips Collaborates with Microsoft to Enhance Healthcare Efficiencies and Productivity
2. Eisner USA, LLC Collaborates with Surgical Review Corp to Provide Innovative Bariatric Devices to Bariatric Surgery Center of Excellence (BSCOE) Participants
3. PeopleStreme Collaborates with SkillSoft for Learning Management Content
4. UCSF collaborates with Zcube to develop new ways to deliver drugs
5. Childrens National collaborates with NIH researchers to identify gene variant in Proteus syndrome
6. Amway One by One Campaign for Children Reaches 7 Million Kids
7. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
8. International Diabetes Federation awards $2 million to 9 global diabetes research projects
9. New Report: $1 Cigarette Tax Increase Would Raise $418.8 Million for Texas and Cut Youth Smoking
10. New Report: $1 Cigarette Tax Increase Would Raise $18.6 Million for Montana and Cut Youth Smoking
11. New Report: $1 Cigarette Tax Increase Would Raise $24.8 Million for Wyoming and Cut Youth Smoking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... Order Custom Tee ... website. No need to be concerned about garment selection, expensive graphic designers, ... all orders are printed and shipped within 5-10 days. And every garment ...
(Date:9/25/2017)... College Station, TX (PRWEB) , ... September 25, ... ... cleanroom solutions, will further expand its Portable, Continuous, Miniature, and Modular (PCMM) collaboration ... into the existing POD-based Oral Solid Dosage line. The new PODs will provide ...
(Date:9/25/2017)... ... 2017 , ... Bobbie Horowitz was hardly able to walk without excruciating pain ... cabaret and theater producer, Horowitz would manage to get to rehearsals on time, but ... City, so she had to take a cab everywhere. , It wasn’t until ...
(Date:9/25/2017)... ... September 25, 2017 , ... Ron Norman, CEO of ... senior, upper-level executives speaking at a business luncheon today, "It is tantamount to ... an asset to be fully realized and activated by the corporations that recognize ...
(Date:9/25/2017)... ... September 25, 2017 , ... “The ... a gripping look at the religious stand in the sensitive matter of ... and compassion. “The Ministry of Reconciliation: A Compassionate and Realistic Approach to Evangelizing ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform ... leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led ...
(Date:9/13/2017)... , Sept. 13, 2017   OrthoAtlanta has been ... Atlanta Football Host Committee (AFHC) for the 2018 College Football ... 8, 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... the AFHC "I,m In" campaign, participating in many activities leading ... ...
Breaking Medicine Technology: